Introduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily
of, but not restricted to the gut. Extraintestinal manifestations (EIMs) are frequently observed …

Background Nonresponse and loss of response to anti‐TNF therapies in Crohn's disease
represent significant clinical problems for which clear management guidelines are lacking …

Guidelines for clinical practice are aimed to indicate preferred approaches to medical
problems as established by scientifically valid research. Double-blind placebo controlled …

Introduction: Although the etiology of inflammatory bowel diseases (IBD) remains unknown,
accumulating evidence suggests that the intestinal tissue damage in these disorders is due …

Although drug development has advanced for autoimmune diseases, many current
therapies are hampered by adverse effects and the frequent destruction or inactivation of …

The major histocompatibility complex (MHC) is one of the most extensively studied regions
in the human genome because of the association of variants at this locus with autoimmune …

Background & Aims: The aim of this study was to evaluate the short-and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

Background and aims: This study evaluates the long-term safety of infliximab in patients with
inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The …

Background Anaemia is a serious complication of Crohn's disease that triggers
hospitalization and, if not interfered with, may lead to death. Aims To systematically …